Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary M Horowitz

Showing results (241-250 of 260) with videos related to

Pageof 26
Sort By:
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Blood|July 31, 2008
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee, Manisha Kukreja, Tao Wang, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2017
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for ProphylaxisMuna Qayed, Tao Wang, Michael T Hemmer, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman, Waleska S Pérez, Hillard M Lazarus, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|September 26, 2013
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIEdward A Copelan, Betty K Hamilton, Belinda Avalos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiationEdward A Copelan, Belinda R Avalos, Kwang Woo Ahn, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myelomaPhilip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
Pageof 26

Showing results (241-250 of 260) with videos related to

Sort By:
Pageof 26
Blood Advances|March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Blood|July 31, 2008
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee, Manisha Kukreja, Tao Wang, et al.
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2017
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for ProphylaxisMuna Qayed, Tao Wang, Michael T Hemmer, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remissionMartin S Tallman, Waleska S Pérez, Hillard M Lazarus, et al.
Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|September 26, 2013
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIEdward A Copelan, Betty K Hamilton, Belinda Avalos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiationEdward A Copelan, Belinda R Avalos, Kwang Woo Ahn, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myelomaPhilip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
Pageof 26